- Curi Bio Inc., a Seattle, WA-based developer of human stem cell-based platforms for drug discovery, raised $6m in Series A financing round
- The round, also led by Dynamk Capital, expected to close with additional investors by the end of Q2 2021
- With this financing round, Dr. Gustavo Mahler, Managing Partner at Dynamk Capital, joined Curi Bio’s as a new board member
- The company also intends to use the funds to scale its existing business and accelerate the development of new innovative human stem cell platforms
- Curi Bio also provides a preclinical discovery platform that combines human stem cells, systems, and data to accelerate the discovery of new medicines
- The Curi Engine is a bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data
